BioNTech is trading 4.3% down at $91.68 after its BNT113 cancer immunotherapy trial failed to meet its first primary endpoint. - Announced October 13, 2026, AHEAD-MERIT found BNT113 plus pembrolizumab did not significantly improve progression-free survival versus pembrolizumab alone. - The trial continues toward its other primary endpoint, overall survival. Reuters reported the result and a nearly 6% premarket decline, while major U.S. indexes were nearly flat.